

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE .	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/016,371		12/10/2001	Ian R. Reid	HO-P02194US0	6234
	26271 7	7590 09/23/2003			
		C & JAWORSKI, LLP		EXAMINER	
	1301 MCKINN SUITE 5100			BAHAR, MOJDEH	
	HOUSTON, TX 77010-3095			ART UNIT	PAPER NUMBER
				1617	
				DATE MAILED: 09/23/2003	1

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Application No.	Applicant(s)				
, Office A.4: Commence	10/016,371	REID, IAN R.				
Office Action Summary	Examiner	Art Unit				
	Mojdeh Bahar	1617				
Period for R ply	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for R ply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is pecified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on $\underline{0}$	<u> 14 June 2003</u> .					
2a) ☐ This action is FINAL . 2b) ☑	This action is non-final.					
3) Since this application is in condition for allo						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4) Claim(s) 1-21 is/are pending in the applicat	4) Claim(s) 1-21 is/are pending in the application.					
4a) Of the above claim(s) <u>10 and 16</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-9,11-15 and 17-21</u> is/are rejected	rejected.					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and Application Papers	d/or election requirement.					
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the	Examiner.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for fore	eign priority under 35 U.S.C. § 119(a	a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority docume	ents have been received.					
2. Certified copies of the priority docume	ents have been received in Applicati	ion No				
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for dome) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 10/016,371

Art Unit: 1617

DETAILED ACTION

Applicant's election without traverse of Group I, claims 1-9, 11-15 and 17-21 in Paper No. 6 is acknowledged.

Claims 10 and 16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invenion, there being no allowable generic or linking claim.

Election was made without traverse in Paper No. 6.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-9, 11-15 and 17-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Ruml et al. (The effect of calcium citrate on bone density in the early and id-postmenopausal period: a randomized placebo-controlled study, abstract, Nov. 1999).

Ruml et al. teaches a method of calcium citrate supplementation in post-menopausal women for a period of two years. It further teaches that the amount of calcium was 400 mg, twice daily.

Note that the host, the amount, and the pharmaceutical active are the same in both Ruml and the instant application. Therefore the increase of HDL would have been inherent by the administration of the Ruml composition and following Ruml's prescribed regimen.

Application/Control Number: 10/016,371

Art Unit: 1617

Page 3

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mojdeh Bahar whose telephone number is (703) 305-1007. The examiner can normally be reached on Monday, Tuesday, Thursday and Friday from 8:30 a.m. to 6:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Mojdeh Bahar Patent Examiner September 22, 2003

SREENI PADMANABHAN

PRIMARY EXAMINER

9/22/N3